Strategic positioning Target neurodegenerative diagnostics and therapies space with APN-1607 as a PET imaging tracer for tauopathies, aligning with rising demand for early and accurate tau detection tools.

Clinical momentum Leverage ongoing Phase 3 activities and recent public listing to engage CROs, contract research and manufacturing organizations, and diagnostic partners for scale-up, trials support, and companion diagnostic development.

Partnership opportunities Capitalize on Alzheimer's Drug Discovery Foundation investment and collaboration history to pursue co-development, funding partnerships, and strategic alliances with biopharma seeking tau-targeted imaging and therapeutic assets.

Service expansion Promote new contract service for high-molecular-weight oligomer tau measurement via high-sensitivity ELISA to labs and biotech firms needing validated, specialized tau analytics for research and biomarker programs.

Financial and growth signals Recent IPO activity and multi-million-dollar funding indicate readiness for commercial partnerships, licensing, or strategic investments; focus outreach to potential acquirers, licensors, and investors interested in neurology-focused platforms with imaging and therapeutic pipelines.